Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?

Hims & Hers Health (HIMS) shares have significantly underperformed, declining 23.3% over the past month, while the S&P 500 gained 1.1% and its industry rose 3.9%. This underperformance is attributed to substantial negative revisions in earnings estimates, with the Zacks Consensus Estimate for the current quarter dropping 51% and the current fiscal year estimate falling 17.9% over the last 30 days. Consequently, HIMS has received a Zacks Rank #4 (Sell), suggesting potential near-term underperformance, further compounded by a 'D' valuation grade indicating it trades at a premium to peers despite strong projected revenue growth.

Analysis

Hims & Hers Health (HIMS) is experiencing significant market pressure, evidenced by a 23.3% stock decline over the past month, which starkly contrasts with gains in both the S&P 500 (+1.1%) and its specific industry (+3.9%). The primary driver for this negative sentiment appears to be substantial downward revisions in analyst earnings estimates. Over the last 30 days, consensus EPS estimates have been reduced by 51% for the current quarter, 17.9% for the current fiscal year, and 22.7% for the next fiscal year. This has culminated in a Zacks Rank #4 (Sell), suggesting near-term underperformance. The company's last reported quarter adds to the concern, as it missed consensus estimates on both revenue (-1.51%) and EPS (-5.56%), with a history of surpassing EPS estimates only once in the last four quarters. This deteriorating earnings outlook is juxtaposed with strong projected revenue growth of 58.9% for the current year and 19% for the next. However, the company's valuation is considered premium relative to its peers, as indicated by a Zacks Value Style Score of 'D', making the stock difficult to justify on a value basis amidst falling profitability expectations.

Key Decisions for Investors

• Given the significant and recent downward revisions to earnings estimates, investors should treat the stock with caution, as the current negative sentiment and Zacks Rank #4 (Sell) signal potential for further near-term underperformance.
• The disconnect between robust projected revenue growth and sharply declining profitability forecasts is a key risk; monitor the next earnings report closely for any signs of margin stabilization or an ability to meet bottom-line expectations.
• Considering the premium valuation, evidenced by a 'D' grade for Value, and the stock's -23.3% one-month return, initiating or adding to long positions may be imprudent until there is a clear positive catalyst or a reversal in the trend of negative earnings revisions.